

Saskatchewan Immunization Manual Amendments June 2022

Instructions: Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

Chapter 4 Documentation

- P. 3 Section 2.1 Immunization Record Confidentiality and Security
 - Bullet #5 now states: Agency policies must be followed for requests regarding the receipt of emailed immunization records.

Chapter 10 Biological Products

- TOC page 3 updated.
- Janssen COVID-19 vaccine
 - Updated product monograph
 - Under Storage and Handling, reference to 6 month for unopened vials revised to 11 months.
- Moderna 6+
 - Under Schedule: (minimum interval of 28 days recommended in SK for healthy individuals.
- Pfizer 12+
 - Under Schedule: (minimum interval of 28 days recommended in SK, but 21 days is acceptable) has been added to criteria.
 - Updated product monograph
- Pfizer 5-11 years
 - Updated product monograph
- Pevnar 13
 - Section B now titled: Medically High-Risk Children Aged 60 Months - 17 Years and Adults 18+ Who Are at Risk of Invasive Pneumococcal Disease
 - Added to text in this section: "... age) and medically high risk adults who are Pneu-C-13 naive are eligible..."
- RotaTeq
 - G-tube administration comment on first page removed, is only on second page now.
 - New bullet: Refer to SIM chapter 8 Appendix 8.4 *Oral Vaccine Administration via Enteral Tube*.
- **NEW!** IMVAMUNE Smallpox and Monkeypox Vaccine (SMV) added
 - **There has been an update to the schedule section, now as per NACI June 2022:**
 - NACI recommends that PEP using a single dose of the Imvamune® vaccine may be offered to individuals with high risk exposures to a probable or confirmed case of monkeypox, or within a setting where transmission is happening. PEP should be offered as soon as possible and within 4 days of last exposure and can be considered up to 14 days since last exposure. PEP should not be offered to individuals who are symptomatic and who meet the definition of suspect, probable or confirmed case.
 - After 28 days, if an individual is assessed as having a predictable ongoing risk of exposure, a second dose may be offered. A second dose should not be offered to individuals who are symptomatic and therefore after medical evaluation meet suspect, probable or confirmed monkeypox case definitions.
- Updated Product Monograph
 - Vivotif
- Varilrix varicella vaccine page 1 of 2
 - Varilrix is only available for severely immunocompromised individuals 1 year and older and specialist approval is required.
 - Appendix 7.2: *Varicella Immunization Referral Form* must be completed to order this vaccine as individual doses from RRPL.
 - Not for general population use.

Saskatchewan Immunization Manual Amendments June 2022

- HepaGam B
 - Updated PM.
 - Contraindications and expected reactions updated.
- HYPER HepB
 - Updated PM
 - Updated contraindications.
- HYPERTET
 - Updated PM.
 - Contraindications and components updated.
- VariZIG
 - Updated PM
 - Contraindications and components updated.

Chapter 11 AEFIS

- TOC updated appendix 11.4
- P. 1 Section 1 Introduction
 - First paragraph now states:
 - **Publicly funded** active immunizing agents
 - Second paragraph now states:
 - **Non-publicly funded active immunizing agents**, passive immunizing agents and diagnostic agents
Health Canada (HC) maintains a surveillance system called **the Canada Vigilance Program, which** monitors adverse reactions...

- P. 12 Appendix 11.4
 - Now states:
Appendix 11.4: Canada Vigilance Program (for non-publicly funded vaccines, Tubersol and passive immunizing agents)

Contact the Canada Vigilance Program by one of the following 3 ways:

1. Report online at www.healthcanada.gc.ca/medeffect
2. Call toll-free at 1-866-234-2345
3. Complete a Canada Vigilance Reporting Form and:
Fax toll-free to 1-866-678-6789, or
Mail to: Canada Vigilance Program

Health Canada

Postal Locator 0701D

Ottawa, Ontario

K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

- P. 15 Appendix 11.5
 - **Smallpox vaccine (historical entry) Sma** and **Smallpox/monkeypox vaccine (SMV)** added to table.

Chapter 12 Anaphylaxis Management

- P. 2 Section 1.2 Presentation
 - First sentence now states, *Changes develop over several minutes and involve **two or more body systems** (e.g., affecting the skin, respiration, circulation, GI system).*

Saskatchewan Immunization Manual Amendments June 2022

Chapter 14 Appendices

- Appendix 14.3: Immunization fact sheets for June
- Updates include product monographs, side effects and the removal of the statement, *Individuals who have a mild illness, with or without a fever, may be asked to defer their routine immunization based on current COVID-19 screening criteria.*